https://www.selleckchem.com/pr....oducts/3-methyladeni
Finite nucleos(t)ide analogue (Nuc) therapy in HBV suppressed hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B may substantially increase hepatitis B surface antigen (HBsAg) loss rate after cessation of therapy, in which "no retreatment" is a strong predictor for HBsAg loss. However, the main safety concern of no retreatment is hepatitis flare leading to hepatic decompensation or even fatality. Hence it is crucial to make retreatment decision that is not too soon to allow sufficient immune clearance facil
Like
Comment
Share
